This study protocol is designed to evaluate the clinical efficacy, safety, and tolerability of HCL001 cell injection in the treatment of decompensated cirrhosis. The aim is to provide stronger evidence for the clinical application of HCL001 cell injection in the treatment of decompensated cirrhosis, thereby attempting to improve patients' survival and quality of life to meet the clinical needs for treating decompensated liver cirrhosis.

Start Date30 Mar 2024

Sponsor / Collaborator

Shanghai Renji Hospital

100 Clinical Results associated with Homologous Allogeneic Hepatocytes(Renji Hospital)

100 Translational Medicine associated with Homologous Allogeneic Hepatocytes(Renji Hospital)

100 Patents (Medical) associated with Homologous Allogeneic Hepatocytes(Renji Hospital)

Literatures (Medical) associated with Homologous Allogeneic Hepatocytes(Renji Hospital)

01 Dec 2024·International Journal of Biological Macromolecules

Generation and epitope mapping of novel neutralizing monoclonal antibodies against glycoprotein E2 of CSFV

Article

Author: Wu, Meng ; Tu, Changchun ; Liu, Zhongdi ; Gong, Wenjie ; Bao, Fei ; Li, Hongwei ; Zhang, Yixiao ; Mi, Shijiang

Classical swine fever virus (CSFV) is a highly contagious and economically important pathogen threatening pig industry worldwide, the envelope glycoprotein E2 of CSFV is the dominant antigen inducing strong antiviral neutralizing immunity. In this study, 7 monoclonal antibodies (mAbs) with neutralizing potency were generated using E2 protein of CSFV Shimen strain (SM) expressed by eukaryotic cells. Their reactivity with 116 CSFV strains in cell cultures and E2 proteins of 10 subgenotypes in western blots showed different CSFV spectrums they recognized. Of them, three (HCL-001, HCL-005 and HCL-010) reacted with all CSFV subgenotypes, while HCL-014 and HCL-002 reacted with most CSFV strains, except for some variants in genotype 2.3. In contrast, mAb HCL-009 reacted only with a few subgenotype 1.1 strains including SM, field strains and some vaccine strains. Interestingly, mAb HCL-018 reacted only with SM and field subgenotype 1.1 strains, not with any vaccine strains. Further epitope mapping using chimeric and site-directed mutated E2 proteins showed that HCL-001, HCL-005 and HCL-010 recognized a conservative epitope motif ¹⁴³SPT¹⁴⁵,L¹⁴⁷, and HCL-002 recognized a conformational epitope with key aa motifs of ⁹⁵GDD⁹⁷,¹⁵⁷RX(D/E)K(R)XFXXR¹⁶⁴. HCL-014 recognized a new conservative epitope with key aa motifs of ⁴¹D,⁵⁸XNVVXRR⁶⁴. HCL-009 and HCL-018 recognized the epitope with key aa motifs of ³⁶D,⁴⁰ND⁴¹,⁴⁵KXI⁴⁷ and ⁶⁹LHXGXLLT⁷⁶, respectively. Taken together, present study has provided not only new insights into the antigenic structure of E2 protein, but also key reagents for antigenic characterization of CSFV strains and development of antibody assay for evaluation of the vaccination efficacy.

100 Deals associated with Homologous Allogeneic Hepatocytes(Renji Hospital)

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Homologous Allogeneic Hepatocytes(Renji Hospital)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation